“…Furthermore, in vivo treatment with the broad Src family inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl)-pyrazolo[3,4-d]pyrimidine (PP2) in rats subjected to ischemic insult resulted in the rescue of ischemic BBB leakage (Takenaga et al, 2009) and improved neurological deficit scores (Bai et al, 2014) in the presence of the inhibitor. Moreover, c-Src has been identified as an upstream regulator of a number of tight junction complex components, including occludin (Takenaga et al, 2009), claudin-5 (Bai et al, 2014), and zona occludens-1 (Morin-Brureau et al, 2011), as well as a modulator of NMDAR activity in neurons (Lu et al, 1999; Yu and Salter, 1999; Rong et al, 2001; Heidinger et al, 2002; Hossain et al, 2012; Tang et al, 2012; Krogh et al, 2014), and a downstream effector of the VEGFR2 signaling pathway (He et al, 1999; Morin-Brureau et al, 2011; Sun et al, 2012; Cao et al, 2015), in addition to its role in cell cycle regulation and proliferation (Boggon and Eck, 2004; Parsons and Parsons, 2004; Hu et al, 2008; Sen and Johnson, 2011; Reinecke and Caplan, 2014). …”